<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

impact of concomitant medication use and immune related adverse events on response to immune checkpoint inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 01 Feb 2020Publisher:Informa UK LimitedJournal:Immunotherapy, volume 12, pages 141-149 (issn: 1750-743X, eissn: 1750-7448,

Copyright policy )Funded by:NIH | Roswell Park Cancer Insti..., NIH | Genomic Evaluation of the..., NIH | Understanding how adrener... +1 projects

Authors: Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; +1 Authors

doi: 10.2217/imt-2019-0064

pmid: 32064978

pmc: PMC7202260

impact of concomitant medication use and immune related adverse events on response to immune checkpoint inhibitors

- Summary
- Subjects
- Metrics

Abstract

Aim: Patients receiving checkpoint inhibitors (CPI) are frequently on other medications for co-morbidities. We explored the impact of concomitant medication use on outcomes. Materials & methods: 210 metastatic cancer patients on CPI were identified and association between concomitant medication use and immune-related adverse events with clinical outcomes was determined. Results: Aspirin, metformin, β-blockers and statins were not shown to have any statistically significant difference on clinical benefit. 26.3% patients with clinical benefit developed rash versus 11.8% without clinical benefit (p < 0.05) on multivariate analysis. Conclusion: Use of common prescription and nonprescription medications in patients with multiple co-morbidities appears safe and does not have an adverse effect on CPI efficacy. The presence of rash predicted for a better response.

Related Organizations

Roswell Park Cancer Institute
United States
Roswell Park Comprehensive Cancer Center
United States

Keywords

Adult, Aged, 80 and over, Male, Middle Aged, Young Adult, Neoplasms, Polypharmacy, Humans, Immunologic Factors, Female, Immunotherapy, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	25
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%